Biogen Idec to Present at the 3rd Annual CITI Biotech Day

September 4, 2008 • Investor Relations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ/BIIB) announced today that its presentation at the CITI Biotech Day will be webcast live via the internet, on Monday, September 8, 2008 at 3:20 p.m. ET. To access the live webcast, please visit Biogen Idec’s Investor Relations section (investor.biogenidec.com). An archived version of the webcast will be available for 14 days following the presentation.

About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com.

 

Contact:

Biogen Idec
Heidi Brewster, 617-679-2812
Investor Relations

thumb
October 14, 2021
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting

CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 ( SOD1 )

Read More
thumb
October 13, 2021
New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosing Real-world analysis shows significantly lower risk of relapse for patients treated with TYSABRI ® compared to Ocrevus ® (ocrelizumab) New

Read More